ArticleFrontiers in microbiology2026
Unraveling the ameliorative effects of Ling-Gui-Zhu-Gan decoction on MASLD: an integrative gut microbiota and lipidomic study.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been continuously increasing. However, the pathogenesis of MASLD is quite complex and involves multiple factors, leading to a lack of targeted therapeutic drugs for MASLD. Ling-Gui-Zhu-Gan Decoction (LGZGD) has demonstrated significant hepatoprotective and lipid-lowering effects, yet its mechanism of action against MASLD remains incompletely understood. Methods: In this study, we established a high-fat diet-induced MASLD rat model to investigate the pharmacological effects of LGZGD on MASLD from the perspectives of gut microbiota and lipidomics. Results: Using UPLC-Q-TOF-MS analysis, we putatively identified 83 chemical components in LGZGD, primarily flavones and terpenoids, which may represent the key active constituents responsible for its ameliorative effects. In MASLD model rats, LGZGD treatment reduced the levels of TC, TG, AST, ALT, and LDL-C in both serum and liver tissue, while increasing HDL-C levels. Analysis of the gut microbiota revealed that LGZGD treatment increased the abundance of Conclusions: This study demonstrates that LGZGD prevents MASLD, and its mechanism of action involves the regulation of gut microbiota and the modulation of lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.